Literature DB >> 27798376

Leveraging contact network structure in the design of cluster randomized trials.

Guy Harling1, Rui Wang2,3, Jukka-Pekka Onnela2, Victor De Gruttola2.   

Abstract

BACKGROUND: In settings like the Ebola epidemic, where proof-of-principle trials have provided evidence of efficacy but questions remain about the effectiveness of different possible modes of implementation, it may be useful to conduct trials that not only generate information about intervention effects but also themselves provide public health benefit. Cluster randomized trials are of particular value for infectious disease prevention research by virtue of their ability to capture both direct and indirect effects of intervention, the latter of which depends heavily on the nature of contact networks within and across clusters. By leveraging information about these networks-in particular the degree of connection across randomized units, which can be obtained at study baseline-we propose a novel class of connectivity-informed cluster trial designs that aim both to improve public health impact (speed of epidemic control) and to preserve the ability to detect intervention effects.
METHODS: We several designs for cluster randomized trials with staggered enrollment, in each of which the order of enrollment is based on the total number of ties (contacts) from individuals within a cluster to individuals in other clusters. Our designs can accommodate connectivity based either on the total number of external connections at baseline or on connections only to areas yet to receive the intervention. We further consider a "holdback" version of the designs in which control clusters are held back from re-randomization for some time interval. We investigate the performance of these designs in terms of epidemic control outcomes (time to end of epidemic and cumulative incidence) and power to detect intervention effect, by simulating vaccination trials during an SEIR-type epidemic outbreak using a network-structured agent-based model. We compare results to those of a traditional Stepped Wedge trial.
RESULTS: In our simulation studies, connectivity-informed designs lead to a 20% reduction in cumulative incidence compared to comparable traditional study designs, but have little impact on epidemic length. Power to detect intervention effect is reduced in all connectivity-informed designs, but "holdback" versions provide power that is very close to that of a traditional Stepped Wedge approach.
CONCLUSION: Incorporating information about cluster connectivity in the design of cluster randomized trials can increase their public health impact, especially in acute outbreak settings. Using this information helps control outbreaks-by minimizing the number of cross-cluster infections-with very modest cost in terms of power to detect effectiveness.

Entities:  

Keywords:  Ebola; Vaccine; cluster randomized trial; epidemic control; network; power

Mesh:

Substances:

Year:  2016        PMID: 27798376      PMCID: PMC5300908          DOI: 10.1177/1740774516673355

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  25 in total

1.  Vaccine testing. Ebola and beyond.

Authors:  Marc Lipsitch; Nir Eyal; M Elizabeth Halloran; Miguel A Hernán; Ira M Longini; Eli N Perencevich; Rebecca F Grais
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Developments in cluster randomized trials and Statistics in Medicine.

Authors:  M J Campbell; A Donner; N Klar
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

3.  Structure and tie strengths in mobile communication networks.

Authors:  J-P Onnela; J Saramäki; J Hyvönen; G Szabó; D Lazer; K Kaski; J Kertész; A-L Barabási
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

4.  The Ebola Epidemic. High hopes for Guinean vaccine trial.

Authors:  Martin Enserink
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

5.  Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis.

Authors:  Steven E Bellan; Juliet R C Pulliam; Carl A B Pearson; David Champredon; Spencer J Fox; Laura Skrip; Alison P Galvani; Manoj Gambhir; Ben A Lopman; Travis C Porco; Lauren Ancel Meyers; Jonathan Dushoff
Journal:  Lancet Infect Dis       Date:  2015-04-14       Impact factor: 25.071

6.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

7.  Global efficiency of local immunization on complex networks.

Authors:  Laurent Hébert-Dufresne; Antoine Allard; Jean-Gabriel Young; Louis J Dubé
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Geographic constraints on social network groups.

Authors:  Jukka-Pekka Onnela; Samuel Arbesman; Marta C González; Albert-László Barabási; Nicholas A Christakis
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

9.  How important is randomisation in a stepped wedge trial?

Authors:  James R Hargreaves; Audrey Prost; Katherine L Fielding; Andrew J Copas
Journal:  Trials       Date:  2015-08-16       Impact factor: 2.279

10.  Quantifying travel behavior for infectious disease research: a comparison of data from surveys and mobile phones.

Authors:  Amy Wesolowski; Gillian Stresman; Nathan Eagle; Jennifer Stevenson; Chrispin Owaga; Elizabeth Marube; Teun Bousema; Christopher Drakeley; Jonathan Cox; Caroline O Buckee
Journal:  Sci Rep       Date:  2014-07-14       Impact factor: 4.379

View more
  6 in total

Review 1.  Improving vaccine trials in infectious disease emergencies.

Authors:  Marc Lipsitch; Nir Eyal
Journal:  Science       Date:  2017-07-14       Impact factor: 47.728

Review 2.  Review of Recent Methodological Developments in Group-Randomized Trials: Part 1-Design.

Authors:  Elizabeth L Turner; Fan Li; John A Gallis; Melanie Prague; David M Murray
Journal:  Am J Public Health       Date:  2017-04-20       Impact factor: 9.308

Review 3.  A Network Approach to Stroke Systems of Care.

Authors:  Kori S Zachrison; Amar Dhand; Lee H Schwamm; Jukka-Pekka Onnela
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-08-13

Review 4.  Review of Recent Methodological Developments in Group-Randomized Trials: Part 2-Analysis.

Authors:  Elizabeth L Turner; Melanie Prague; John A Gallis; Fan Li; David M Murray
Journal:  Am J Public Health       Date:  2017-05-18       Impact factor: 9.308

5.  Simulations for designing and interpreting intervention trials in infectious diseases.

Authors:  M Elizabeth Halloran; Kari Auranen; Sarah Baird; Nicole E Basta; Steven E Bellan; Ron Brookmeyer; Ben S Cooper; Victor DeGruttola; James P Hughes; Justin Lessler; Eric T Lofgren; Ira M Longini; Jukka-Pekka Onnela; Berk Özler; George R Seage; Thomas A Smith; Alessandro Vespignani; Emilia Vynnycky; Marc Lipsitch
Journal:  BMC Med       Date:  2017-12-29       Impact factor: 8.775

6.  Choices in vaccine trial design in epidemics of emerging infections.

Authors:  Rebecca Kahn; Annette Rid; Peter G Smith; Nir Eyal; Marc Lipsitch
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.